Inhibrx Stock Investor Sentiment

INBX Stock  USD 14.86  0.78  5.54%   
Slightly above 76 percent of all Inhibrx's investors are aggressively thinking of buying. The analysis of the overall investor sentiment regarding Inhibrx suggests that a fairly large number of traders are excited. Inhibrx's investing sentiment can be driven by a variety of factors including economic data, Inhibrx's earnings reports, geopolitical events, and overall market trends.
  

Inhibrx Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Inhibrx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at thelincolnianonline.com         
Inhibrx, Inc. Director Jon Faiz Kayyem Buys 69,686 Shares
news
few days ago at investing.com         
Inhibrx Biosciences director Jon Faiz Kayyem buys 1.52m in stock
Investing News at Macroaxis
few days ago at www.macroaxis.com         
Acquisition by Kayyem Jon Faiz of 18750 shares of Inhibrx at 14.1921 subject to Rule 16b-3
Macroaxis News
six days ago at www.macroaxis.com         
Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3
Macroaxis News
over a week ago at finance.yahoo.com         
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. institutional investors w...
Yahoo News
over a week ago at gurufocus.com         
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - BioSpace
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
Yahoo News
over a month ago at www.macroaxis.com         
Disposition of 15000 shares by Kayyem Jon Faiz of Inhibrx at 24.78 subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Acquisition by Vuori Kristiina Md of 6667 shares of Inhibrx at 15.0 subject to Rule 16b-3
Macroaxis News
over a month ago at news.google.com         
Inhibrx Biosciences SWOT analysis cash-rich biotech stock faces pivotal year - Investing.com
Google News at Macroaxis
over two months ago at thelincolnianonline.com         
Inhibrx, Inc. Short Interest Update
news
over two months ago at investing.com         
Acquisition by Mark Lappe of 13037 shares of Inhibrx at 17.13 subject to Rule 16b-3
Investing News at Macroaxis
over two months ago at gurufocus.com         
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc
Gurufocus Stories at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Mark Lappe of 26963 shares of Inhibrx at 15.05 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Inhibrx that are available to investors today. That information is available publicly through Inhibrx media outlets and privately through word of mouth or via Inhibrx internal channels. However, regardless of the origin, that massive amount of Inhibrx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inhibrx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inhibrx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inhibrx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inhibrx alpha.

Inhibrx Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Mark Lappe of 26000 shares of Inhibrx at 15.29 subject to Rule 16b-3
09/06/2024
2
Acquisition by Mark Lappe of 9500 shares of Inhibrx at 15.21 subject to Rule 16b-3
09/09/2024
3
Acquisition by Mark Lappe of 8500 shares of Inhibrx at 15.19 subject to Rule 16b-3
09/10/2024
4
Acquisition by Vuori Kristiina Md of 6457 shares of Inhibrx at 15.07 subject to Rule 16b-3
09/11/2024
5
Acquisition by Mark Lappe of 26963 shares of Inhibrx at 15.05 subject to Rule 16b-3
09/12/2024
6
Acquisition by Mark Lappe of 13037 shares of Inhibrx at 17.13 subject to Rule 16b-3
09/16/2024
7
Acquisition by Vuori Kristiina Md of 6667 shares of Inhibrx at 15.0 subject to Rule 16b-3
10/03/2024
8
Disposition of 15000 shares by Kayyem Jon Faiz of Inhibrx at 24.78 subject to Rule 16b-3
10/23/2024
9
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - BioSpace
11/14/2024
10
Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3
11/19/2024
11
Acquisition by Kayyem Jon Faiz of 18750 shares of Inhibrx at 14.1921 subject to Rule 16b-3
11/20/2024

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.